中国科技论文统计源期刊 中文核心期刊  
美国《化学文摘》《国际药学文摘》
《乌利希期刊指南》
WHO《西太平洋地区医学索引》来源期刊  
日本科学技术振兴机构数据库(JST)
第七届湖北十大名刊提名奖  
医药导报, 2017, 36(8): 905-908
doi: 10.3870/j.issn.1004-0781.2017.08.015
不同剂量盐酸羟考酮对患者自主呼吸及意识的影响
Effects of Different Doses of Oxycodone Hydrochloride on Spontaneous Breathing and Consciousness Level of Patients
于翠萍, 范婷, 王培

摘要:

目的 评价不同剂量盐酸羟考酮对患者自主呼吸及意识的影响,为其临床应用提供理论依据。方法 60例行择期手术患者,按羟考酮的不同剂量随机均分3组,分别为羟考酮0.05 mg·kg-1组(P1组),0.1 mg·kg-1组(P2组),0.2 mg·kg-1组(P3组)。3组记录注药前即刻(t0)及注药后1~15 min 内(每分钟记录一次)患者呼吸频率(RR)、呼气末CO2分压(PETCO2)、脉搏血氧饱和度(SpO2)和脑电双频指数(BIS)的变化,并进行警觉/镇静观察评分(OAA/S),同时观察各组患者注药后的不良反应。结果 注药10 min内,与注药前数值比较,P1组RR、SpO2、PETCO2、BIS及OAA/S变化差异无统计学意义(P>0.05),P1组无患者出现呼吸抑制;P2组的RR变化差异有统计学意义(P<0.05),BIS虽然有下降但均大于85,SpO2、PETCO2及OAA/S变化差异无统计学意义(P>0.05),P2组有3例出现呼吸频率<10次·min-1,但SpO2均大于94%; P3组的RR、SpO2、PETCO2、BIS及OAA/S变化差异有统计学意义(P<0.05),P3组有12例出现呼吸频率<10次·min-1,同时有8例SpO2<94%。随剂量增加,呼吸抑制例数增加,且差异有统计学意义(P<0.05)。注药15 min后,与注药前数值比较,P1组、P2组的RR、SpO2、PETCO2、BIS及OAA/S变化差异无统计学意义(P>0.05),P3组RR与注药前比较差异有统计学意义(P<0.05),P3组的SpO2、PETCO2、BIS及OAA/S变化差异无统计学意义(P>0.05)。P1组、P2组患者均未出现胸壁僵直、恶心呕吐、 呛咳等不良反应,P3组有3例患者用药后5 min诉恶心;2例诉前胸皮肤瘙痒但未见皮肤潮红。结论 随剂量增加,盐酸羟考酮对患者呼吸及意识的影响逐渐加重;剂量为0.05 mg·kg-1时对呼吸及意识无明显影响;剂量为0.1,0.2 mg·kg-1时用药后5~10 min,呼吸抑制最明显及镇静作用最强。用药15 min后,0.1 mg·kg-1剂量组基本恢复至用药前水平;0.2 mg·kg-1剂量组呼吸频率仍低于用药前水平。

关键词: 羟考酮 ; 盐酸 ; 呼吸抑制 ; 镇静

Abstract:

Objective To assess the effects of different doses of oxycodone hydrochloride on spontaneous breathing and consciousness level of patients,so as to provide theoretical basis for its clinical application.Sixty patients undergoing elective surgery were randomly divided into 3 groups:0.05 mg·kg-1 oxycodone group (group P1),0.1 mg·kg-1 oxycodone group (group P2),0.2 mg·kg-1 oxycodone group (group P3).Changes of respiratory rate (RR),end tidal carbon dioxide partial pressure (PETCO2),saturation of blood oxygen (SpO2) and bispectral index (BIS) were recorded in patients before injection (t0) and 1-15 min after injection (once per min);the Observer's Assessment of Alertness/Sedation Scale (OAA /S) were recorded.At the same time,the adverse reactions were observed after drug injection in each group. Results In 10 min after injection there were no significant differences in the RR,SpO2,PETCO2,BIS and OAA/S in group P1 as compared with those before injection (P>0.05).The patients had no respiratory depression in group P1.In group P2,RR had a significant decrease (P<0.05),BIS had decreased but were greater than 85;there were no significant differences in the SpO2,PETCO2 and OAA/S (P>0.05).The P2 group had 3 cases with respiratory frequency<10 per min,but SpO2 were all greater than 94%.In group P3,There were significant differences in the RR,SpO2,PETCO2,BIS and OAA/S (P<0.05).The P3 group had 12 cases of respiratory frequency <10 per min,at the same time there were 8 patients with SpO2 less than 94%.With the increasing dose,the frequency of respiratory inhibition increased,and there were statistical differences (P<0.05).In 15 min after injection,RR,SpO2,PETCO2,BIS and OAA/S were not significantly different in group P1 and P2 as compared with those before injection (P>0.05).In group P3,RR was significantly different after injection (P<0.05).There were no significant differences in the SpO2,PETCO2,BIS and OAA/S in group P3 after injection (P>0.05).No patients complained with chest wall stiffness,nausea and vomiting,cough and other adverse reactions in group P1 and P2.In group P3,three patients had nausea 5 min after injection,two patients complained of chest skin itching but no skin flushing. Conclusion With the increasing dose,effect of oxycodone hydrochloride on breathing and consciousness level of patients gradually increased.Injection of oxycodone hydrochloride 0.05 mg·kg-1 had no obvious effect on breathing and consciousness.After injection of oxycodone hydrochloride 0.1 and 0.2 mg·kg-1 for 5 to 10 min,respiration inhibition and sedative effect were the most obvious.Fifteen min after injection,the 0.1 mg·kg-1 dose group recovered to the level before,the respiratory rate of the 0.2 mg·kg-1 dose group was still lower than that before the injection.

Key words: Oxycodone hydrochloride ; Respiration inhibition ; Sedation

盐酸羟考酮是纯阿片μ和κ受体激动药,其药理作用部位主要是中枢神经系统和平滑肌[1]。是目前临床上唯一可使用的阿片双受体激动药,该药起效快,阿片类药物不良反应较轻,不仅对伤害性疼痛,也对内脏痛和神经病理性疼痛有较好的治疗作用[2]。羟考酮与阿片μ受体亲和力为吗啡的1/5~1/10,也与κ受体结合而发挥镇痛作用。有研究认为κ受体兴奋可产生镇痛和减轻内脏痛作用,但不引起精神欣快、胃肠道蠕动抑制和呼吸抑制作用[3]。目前多数研究观察的是羟考酮术后镇痛的有效性和安全性[4-5],而有关羟考酮呼吸抑制的研究较少[6]。笔者观察了不同剂量羟考酮对患者自主呼吸及意识的影响,从而为该药的临床安全应用提供理论依据。

1 资料与方法
1.1 临床资料

选择清华大学玉泉医院2015年11月—2016年4月择期全身麻醉下行手术的患者60例,ASA Ⅰ或Ⅱ级,年龄18~60岁,体质量45~75 kg,体重指数(BMI)18.5~25 kg·(cm2)-1。神志清楚,Mallapatti分级1或2 级,术前均无明显循环、呼吸系统疾病,无明显肝肾功能障碍,无镇痛药或镇静药、抗抑郁药长期使用史,无酒精滥用史;近期无镇吐药和抗瘙痒药物服药史。所有患者均签署知情同意,并由该院伦理委员会批准。按照手术时间顺序将患者编号为1~60,随机分为3组,每组20例,根据CHANG等[6]的研究确定每组盐酸羟考酮剂量。分别给予盐酸羟考酮注射液0.05 mg·kg-1(P1组),0.1 mg·kg-1(P2组),0.2 mg·kg-1(P3组)。

1.2 治疗方法

考虑到部分患者将出现呼吸抑制,研究在气管插管全麻前15 min内进行,随后进入常规的全麻诱导过程。所有患者术前常规禁食、禁饮8 h,不用术前药物。入室后自主呼吸室内空气。监测无创血压(BP)、心率(HR)、脉搏血氧饱和度(SpO2)和脑电双频指数(BIS),患者鼻腔内置入细导管连接呼气末二氧化碳监测仪监测患者的呼吸频率(RR)和呼气末CO2分压(PETCO2)。不吸氧状态下记录各数据基础值。开放前臂外周静脉。盐酸羟考酮注射液(萌蒂制药有限公司生产,规格:1 mL:10 mg,批准文号:国药准字BJ940)用0.9%氯化钠注射液稀释至1 mg·mL-1,各组均经静脉缓慢推注,时间为1 min。P1组给予盐酸羟考酮注射液0.05 mg·kg-1;P2组给予盐酸羟考酮注射液0.1 mg·kg-1;P3组给予盐酸羟考酮注射液0.2 mg·kg-1

1.3 观察指标

记录注药前即刻(t0)、注药后1~15 min内[每分钟记录1次,t1:注药10 min内最低(高)值,t2:注药后15 min]RR、PETCO2、SpO2 及BIS的变化,并进行警觉/镇静观察评分(OAA/S)。同时观察3组患者注药后的不良反应(胸壁僵直、呼吸抑制、恶心呕吐、呛咳、皮肤瘙痒或皮肤潮红)。OAA/S镇静评级标准为:5级,对正常语调的呼名反应迅速;4级,对正常语调的呼名反应冷淡;3级,仅对大声或反复呼名有反应;2级,仅对轻度的摇推肩膀或头部有反应;1级,对轻度推摇无反应;0级,对挤捏斜方肌无反应。呼吸抑制的标准:RR<10次·min-1或SpO2≤92%[7]。观察过程中符合上述两个标准单独或同时出现皆判为出现呼吸抑制。若出现呼吸抑制,提醒患者深呼吸并给予面罩吸氧5 L·min-1,必要时行辅助呼吸。若出现严重意外,如胸壁僵直立即麻醉诱导行气管插管。

1.4 统计学方法

采用SPSS19.0版统计学软件进行分析,计量资料以均数±标准差( x ¯ ±s)表示,组间比较采用单因素方差分析,组内比较采用配对t检验,计数资料比较采用χ2检验,以P<0.05为差异有统计学意义。

2 结果
2.1 3组患者一般资料比较

3组患者年龄、体质量、性别差异无统计学意义。见表1。

表1 3组患者一般资料比较
Tab.1 Comparison of baseline data among three groups of patients
组别 例数 性别 年龄/
体质量/
kg
BMI/
[kg·(m2)-1]
男/例 女/例
P1组 20 10 10 47.5±6.5 60.5±10.6 21.5±3.3
P2组 20 8 12 44.9±8.7 63.1±9.9 22.1±2.9
P3组 20 9 11 46.0±8.2 61.4±10.1 23.6±2.4

表1 3组患者一般资料比较

Tab.1 Comparison of baseline data among three groups of patients

2.2 3组患者不同时间点呼吸状态的比较

注药10 min内,与注药前数值比较,P1组的RR变化不显著,P2、P3组RR有显著下降(P<0.05),且P3组下降程度较P2大;P1组、P2组的SpO2变化不显著(P>0.05),P3组的SpO2显著下降(P<0.05),最低降至70%;P1组、P2组的PETCO2变化不显著(P>0.05),P3组的PETCO2显著升高(P<0.05)。注药15 min时,与注药前数值比较,P1组、P2组的RR变化不显著,P3组RR与注药前比仍有下降(P<0.05);P1组、P2组、P3组的SpO2、PETCO2与注药前比较变化差异无统计学意义(P>0.05)。见表2。

表2 3组患者注药前后不同时间点RR、SpO2 及PETCO2的比较
Tab.2 Comparison of RR,SpO2 and PETCO2 among three groups of patients at different time points before and after drug injection x¯±s,n=20
组别与时间 RR/
(次·min-1)
SpO2/
%
PETCO2/
kPa
P1组
t0 17.6±1.2 98.8±1.2 5.12±0.33
t1 16.2±2.1 97.3±2.3 5.25±0.43
t2 16.6±2.4 97.8±2.6 5.13±0.40
P2组
t0 17.8±1.6 98.6±1.8 5.20±0.24
t1 13.1±2.6*1 94.7±5.5 5.55±0.47
t2 15.7±2.2 95.6±6.9 5.40±0.36
P3组
t0 17.1±1.3 98.4±1.9 5.13±0.25
t1 11.6±3.1*1 86.1±5.6*1 6.13±0.61*1
t2 13.8±2.5*1*2 92.1±3.5*1*2 5.49±0.49*2

Compared with t0 at the same group, *1P<0.05;compared with P1 group at the same time group, *2P<0.05

与同组t0比较,*1P<0.05;与P1组同时间点比较,*2P<0.05

表2 3组患者注药前后不同时间点RR、SpO2 及PETCO2的比较

Tab.2 Comparison of RR,SpO2 and PETCO2 among three groups of patients at different time points before and after drug injection x¯±s,n=20

2.3 3组发生呼吸抑制情况比较

注药10 min内,P1组无患者出现呼吸抑制;P2组有3例出现呼吸频率<10次·min-1,但SpO2均大于94%;P3组有12例出现呼吸频率<10次·min-1,同时有8例SpO2小于94%。随剂量增加,呼吸抑制例数增加,且有差异有统计学意义(P<0.05)。注药15 min时,P1组、P2组无患者出现呼吸抑制;P3组有5例呼吸频率<10次·min-1,其中有3例SpO2小于94%。P1、P3组比较差异有统计学意义(P<0.05)。见表3。

表3 3组患者呼吸抑制发生率比较
Tab.3 Comparison of the incidence of respiratory depression among three groups of patients
组别 例数 t1 t2 χ2 P
% %
P1组 20 0 0.0 0 0.0
P2组 20 3 15.0 0 0.0 3.243 0.231
P3组 20 12 60.0 5 25.0 5.013 0.054
χ2 20.800 10.909
P 0.000 0.004

表3 3组患者呼吸抑制发生率比较

Tab.3 Comparison of the incidence of respiratory depression among three groups of patients

2.4 3组BIS及镇静评分(OAA/S)比较

注药10 min内,与注药前数值比较,P1组的BIS无显著性变化;P2组虽有下降但均大于85;P3组BIS有显著下降(P<0.05),最低降至65。P1组、P2组的OAA/S变化不显著(P>0.05);P3组的OAA/S显著下降(P<0.05)。注药后15 min,与注药前数值比较,P1、P2、P3组的BIS、OAA/S变化不显著(P>0.05)。见表4。

Tab.4 Comparison of BIS and OAA/S among three groups of patients 分,x¯±s,n=20
组别与时间 BIS OAA/S
P1组
t0 95.4±0.8 5.0±0.0
t1 92.2±1.5*1 5.0±0.0
t2 93.1±1.2*2 5.0±0.0
P2组
t0 95.1±0.6 5.0±0.0
t1 89.8±1.5*1 4.8±0.4
t2 93.0±1.3*1*2 4.9±0.3
P3组
t0 94.9±0.7 5.0±0.0
t1 83.5±5.5*1 3.5±0.7*1
t2 91.1±1.5*1*2 4.6±0.5*1*2

Compared with t0 in the same group, *1P<0.05;compared with P1 group at the same time point, *2P<0.05

与同组t0比较,*1P<0.05;与P1组同时间点比较,*2P<0.05

Tab.4 Comparison of BIS and OAA/S among three groups of patients 分,x¯±s,n=20

2.5 3组患者不良反应比较

P1组、P2组患者均未出现胸壁僵直、恶心呕吐、 呛咳的症状。P3组有3例患者在用药后5 min诉恶心,未行特殊处理,15 min后恶心明显减轻;2例诉前胸皮肤瘙痒但未见皮肤潮红,未行特殊处理,15 min后瘙痒明显缓解。出现不良反应的5例患者用量均大于10 mg。

3 讨论

呼吸抑制是阿片类药物最主要的不良反应,虽然部分临床研究表明盐酸羟考酮呼吸抑制作用较轻具有较高的安全性[8],但 CHANG等[6]研究表明羟考酮产生剂量依赖性的呼吸抑制。羟考酮注射液静脉注射后2~3 min即可观察到药效反应,且5 min达峰值[9]。本研究发现静注羟考酮注射液后患者最低RR及最低SpO2的出现时间多在给药后5~8 min,并呈现先降后升的特点。因此,笔者将其对呼吸影响的观察期定为给药后15 min。OLKKOLA等[10]研究表明静脉注射0.1 mg·kg-1羟考酮后,最小平均通气率和呼气末最大平均二氧化碳浓度均发生在应用羟考酮的8 min内,与笔者的观察结果一致。笔者把羟考酮按不同剂量分为P1组、P2组、P3组,结果显示羟考酮静脉注射对呼吸的抑制有剂量依赖性。盐酸羟考酮0.05 mg·kg-1组对RR、SpO2及PETCO2无明显影响; 0.1 mg·kg-1组可减慢RR,但15 min时可恢复至用药前,对SpO2及PETCO2无明显影响;0.2 mg·kg-1组对患者RR、SpO2及PETCO2均有明显影响,用药后15 min时SpO2及PETCO2恢复至用药前但RR仍慢于用药前。因此低于0.1 mg·kg-1羟考酮对患者呼吸影响较小。吴周全等[4]研究发现在关腹前给予0.1 mg·kg-1羟考酮既能提供良好的镇痛效果,又不影响患者的苏醒。

BIS是目前以脑电来判断镇静水平和监测麻醉深度较为准确的一种方法。一般认为BIS值85~100为正常状态,65~85为镇静状态,40~65为麻醉状态,低于40可能呈现爆发抑制。GAJRAJ等[11]研究中以对言语指令无反应为意识消失标准时,意识存在的BIS值:85±8,意识消失的BIS值:67±10。本研究结果显示:盐酸羟考酮0.05 mg·kg-1 组及0.1 mg·kg-1 组给药前后BIS变化不显著,OAA/S评分大多为4~5分;盐酸羟考酮0.2 mg·kg-1 组给药后10 min内BIS下降明显,最低降至65。OAA/S评分多为3~4分,镇静作用较大。但给药后15 min BIS大多恢复至85以上,OAA/S评分多为4~5分。

3组不良反应中发生最多的是一过性呼吸抑制,其次为恶心和皮肤瘙痒。主要出现于盐酸羟考酮0.2 mg·kg-1的患者中,但在用药后15 min,多数不良反应可明显减轻。这与以往报道一致。HAO等[12]对疼痛患者静脉注射盐酸羟考酮注射液后的药动学研究发现,单次静脉注射盐酸羟考酮10 mg时未出现严重不良反应。

综上所述,随剂量增大,盐酸羟考酮对患者呼吸及意识的影响逐渐加重;剂量为0.05 mg·kg-1时对呼吸及意识无明显影响;剂量为0.1,0.2 mg·kg-1时用药后5~10 min,呼吸抑制最明显及镇静作用最强。用药后15 min,0.1 mg·kg-1基本恢复至用药前水平;0.2 mg·kg-1呼吸频率仍低于用药前水平。

The authors have declared that no competing interests exist.

参考文献

[1] 许幸,吴新民,薛张纲,.盐酸羟考酮注射液用于全身麻醉者术后镇痛的有效性和安全性:前瞻性随机盲法多中心阳性对照临床研究[J].中华麻醉学杂志,2013,33(3):269-274.
目的 评价盐酸羟考酮注射液用于全麻患者术后镇痛的有效性和安全性.方法 本研究为前瞻性、随机、盲法、多中心、阳性对照临床研究.选择择期全麻下腹部手术和骨科手术患者240例,年龄18 ~64岁、体重40 ~ 95 kg、性别不限、ASA分级Ⅰ或Ⅱ级.采用随机数字表法,将其分为2组(n=120):硫酸吗啡注射液组(M组)和盐酸羟考酮注射液组(O组).术毕拔除 气管导管或喉罩后当患者主诉疼痛时,立即静脉注射吗啡或羟考酮1 mg,必要时重复给药,直至VAS评分≤40 mm,随后开启PCA泵(0.9%生理盐水将研究药物稀释至0.5 mg/ml,总量400 ml)行术后PCIA镇痛48 h,背景输注速率0.5 mg/h,PCA量吗啡或羟考酮1 mg/次,锁定时间5 min.疗效指标:于用药后3、24、48 h时行静态和动态VAS评分,并行非劣效检验.记录术后48 h内研究药物总用量、补救镇痛药物使用情况、PCA无效按压次数和总次数、镇痛满意度.安全性指标:记录用药后72 h内不良事件的发生情况,并行实验室检查(血常规、尿常规和血生化检查).结果 2组各时点静态和动态VAS评分、补救镇痛率、PCA无效按压次数和总按压次数、镇痛满意度、研究药物总用量、不良事件比较差异无统计学意义 (P>0.05).2组均无严重不良事件发生.不良事件中发生率最高的是恶心,其次为呕吐.2组恶心、呕吐发生率和严重程度比较差异无统计学意义 (P>0.05),而骨科手术患者O组恶心、呕吐的发生率低于M组(P<0.05).2组其他不良事件及实验室检查异常发生率均较低.2组各时点静态和动 态VAS评分均数之差的95%可信区间皆在15 mm之内(假设非劣效检验界值).结论 盐酸羟考酮注射液术后PCIA可安全有效地减轻中、大型手术后患者疼痛,其镇痛效果与硫酸吗啡注射液相似,而骨科手术患者应用盐酸羟考酮注射液术后 PCIA镇痛时恶心、呕吐的发生较应用硫酸吗啡注射液时低,两药的镇痛效能比接近1∶1.
[本文引用:1]
[2] 徐建国. 盐酸羟考酮的药理学和临床应用[J].临床麻醉学杂志,2014,30(5):511-513.
正盐酸羟考酮,化学名称为4、5-环氧基-14-羟基-3-甲氧基-17甲基吗啡烷-6-酮盐酸盐,是阿片类生物碱的半合成蒂巴因衍生物,为纯阿片μ和κ受体激动药。由于可广泛应用于中、重度急慢性疼痛和癌痛的治疗,现有片剂、控缓释片剂、注射剂、栓剂等多种剂型。药效学羟考酮与吗啡、芬太尼药动力学参数的比较(见表1)。
URL    
[本文引用:1]
[3] STAAHL C,DIMCEVSKI G,ANDERSEN S D,et al.Differ-ent effect of opioids in patients with chronic pancrdatitis:an experimental pain study[J].Scand J Ganstroenterol,2007,42(3):383-390.
[本文引用:1]
[4] 吴周全,邹志清,陈勇.不同剂量羟考酮对腹部手术后急性疼痛的抑制作用[J].临床麻醉学杂志,2015,31(2):161-163.
[本文引用:2]
[5] 许幸,吴新民,薛张纲,.盐酸羟考酮注射液用于全麻患者术后镇痛的有效性和安全性:前瞻性、随机、盲法、多中心、阳性对照临床研究[J].中华麻醉学杂志,2013,33(3):269-274.
目的 评价盐酸羟考酮注射液用于全麻患者术后镇痛的有效性和安全性.方法 本研究为前瞻性、随机、盲法、多中心、阳性对照临床研究.选择择期全麻下腹部手术和骨科手术患者240例,年龄18 ~64岁、体重40 ~ 95 kg、性别不限、ASA分级Ⅰ或Ⅱ级.采用随机数字表法,将其分为2组(n=120):硫酸吗啡注射液组(M组)和盐酸羟考酮注射液组(O组).术毕拔除 气管导管或喉罩后当患者主诉疼痛时,立即静脉注射吗啡或羟考酮1 mg,必要时重复给药,直至VAS评分≤40 mm,随后开启PCA泵(0.9%生理盐水将研究药物稀释至0.5 mg/ml,总量400 ml)行术后PCIA镇痛48 h,背景输注速率0.5 mg/h,PCA量吗啡或羟考酮1 mg/次,锁定时间5 min.疗效指标:于用药后3、24、48 h时行静态和动态VAS评分,并行非劣效检验.记录术后48 h内研究药物总用量、补救镇痛药物使用情况、PCA无效按压次数和总次数、镇痛满意度.安全性指标:记录用药后72 h内不良事件的发生情况,并行实验室检查(血常规、尿常规和血生化检查).结果 2组各时点静态和动态VAS评分、补救镇痛率、PCA无效按压次数和总按压次数、镇痛满意度、研究药物总用量、不良事件比较差异无统计学意义 (P>0.05).2组均无严重不良事件发生.不良事件中发生率最高的是恶心,其次为呕吐.2组恶心、呕吐发生率和严重程度比较差异无统计学意义 (P>0.05),而骨科手术患者O组恶心、呕吐的发生率低于M组(P<0.05).2组其他不良事件及实验室检查异常发生率均较低.2组各时点静态和动 态VAS评分均数之差的95%可信区间皆在15 mm之内(假设非劣效检验界值).结论 盐酸羟考酮注射液术后PCIA可安全有效地减轻中、大型手术后患者疼痛,其镇痛效果与硫酸吗啡注射液相似,而骨科手术患者应用盐酸羟考酮注射液术后 PCIA镇痛时恶心、呕吐的发生较应用硫酸吗啡注射液时低,两药的镇痛效能比接近1∶1.
[本文引用:1]
[6] CHANG S,MANEY K,PHILLPS J,et al.A comparison of the respiratory effects of oxycodone versus morphine:a randomised,double-blind,placebo-controlled investigation[J].Anaesthesia,2010,65(10):1007-1012.
Oxycodone's respiratory profile (particularly the extent of respiratory depression in comparison to morphine) remains to be fully characterised in the peri-operative period. We randomly assigned ASA 1-2 adults for elective surgery under general anaesthesia to receive saline, morphine 0.1 mg.kg6301, or oxycodone 0.05 mg.kg6301, 0.1 mg.kg6301, or 0.2 mg.kg(-1) . Results were obtained from six patients in the saline group, 12 patients in the groups receiving morphine 0.1 mg.kg6301, oxycodone 0.05 mg.kg6301 and 0.1 mg.kg6301, and from 10 patients who received oxycodone 0.2 mg.kg6301. Patients were breathing spontaneously and minute ventilation monitored with a wet wedge spirometer for 30 min. All active groups demonstrated significant respiratory depression compared to saline (p < 0.0001 for all groups). The mean (SD) reduction in minute volume from baseline was 22.6% (10.4%) for the morphine 0.1 group and 53.3% (27.2%), 74.4% (12.9%) and 88.6% (13.5%) for the oxycodone 0.05, 0.1 and 0.2 groups, respectively, with significant dose dependent differences between oxycodone groups (p = 0.0007). The extent and speed of onset of oxycodone induced respiratory depression was dose dependent and greater than an equivalent dose of morphine.
DOI:10.1111/j.1365-2044.2010.06498.x      PMID:20712805      URL    
[本文引用:3]
[7] DERRODE N,LEBRUN F,LEVRON J C,et al.Influence of peroperative post operative pain after major abdominal surgery:sufentanil TCI versus remifentanil TCI.A randominzed,controlled study[J].Br J Anaesth,2003,91(6):842-849.
Sufentanil and remifentanil are characterized by two different pharmacokinetic profiles. The aim of this study was to compare the effects of sufentanil and remifentanil administered using target-controlled infusion (TCI) on recovery and postoperative analgesia after major abdominal surgery.Thirty adult patients scheduled for open colorectal surgery were included in a prospective, randomized study. Sufentanil TCI (sufentanil group) or remifentanil TCI (remifentanil group) was administered during surgery. In the remifentanil group, 30 min before the anticipated end of surgery, morphine 0.15 mg x kg(-1) was administered i.v. In the sufentanil group, an effect-site concentration of 0.25 ng x ml(-1) was targeted at extubation. In both groups, postoperative pain was controlled by titration of i.v. morphine and then patient-controlled analgesia with morphine.The extubation time was similar in the two groups (mean (SD) 13 (6) and 14 (6) min in the sufentanil and remifentanil groups respectively). Visual analogue scale scores were significantly greater during the first 2 h after tracheal extubation in the remifentanil group than in the sufentanil group. The time to first analgesic request in the postanaesthesia care unit was significantly longer in the sufentanil group than in the remifentanil group (55 (64) (range 2-240) vs 11 (7) (1-29) min; P<0.001). The cumulative morphine dose for titration was significantly greater in the remifentanil group (P<0.01). The cumulative morphine dose used during titration and patient-controlled analgesia was significantly greater in the remifentanil group 4, 12 and 24 h after extubation (P<0.05).TCI sufentanil (0.25 ng ml(-1) effect-site concentration at extubation) is more effective than the intraoperative combination of remifentanil TCI infusion with morphine bolus (0.15 mg x kg(-1)) for postoperative pain relief after major abdominal surgery and does not compromise extubation and recovery.
DOI:10.1093/bja/aeg263      PMID:14633756      URL    
[本文引用:1]
[8] KALSO E,POYHIA R,ONNELA P,et al.Intravenous mor-phine and oxycodone for pain after abdominal surgery[J].Acta Anaesthesiol Scand,1991,35(7):642-646.
Intravenous morphine and oxycodone were given double blind in doses of 0.05 mg/kg after major abdominal surgery to 39 patients. The dosing interval was 5 min, until the patient did not want any further analgesics. Less oxycodone was needed than morphine, both to achieve the "first state of pain relief" (13.2 mg vs. 24.9 mg) and during the whole 2-h study period (21.8 mg vs. 34.2 mg). The "first state of pain relief" was achieved faster (28 min vs. 46 min) and lasted longer (39 min vs. 27 min) with oxycodone than morphine. Morphine caused more sedation and a greater decrease in the mean arterial blood pressure than oxycodone. In other respects the two opioids were comparable.
DOI:10.1111/j.1399-6576.1991.tb03364.x      PMID:1785245      URL    
[本文引用:1]
[9] 刘玉明,姚志雄,王金叶.羟考酮注射液的药理作用及临床应用[J].海峡药学,2015,27(4):115-118.
羟考酮注射液是羟考酮的一种新剂型,能有效缓解术后疼痛和癌症疼痛,并且能避免口服制剂的不良反应,本文概述羟考酮注射液的药理作用和临床应用。
[本文引用:1]
[10] OLKKOLA K T,HAMUNEN K,SEPPALA T,et al.Pharma-cokinetics and ventilatory effects of intravenous oxycodone in postoperative children(see comments)[J].Brit J Clin Pharm,1994,38(1):71-76.
1. Oxycodone hydrochloride (0.1 mg kg-1) was given by intravenous bolus to 18 children after ophthalmic surgery. Plasma was sampled for up to 8 h. Blood pressure, heart rate, peripheral arteriolar oxygen saturation, end-tidal carbon dioxide and halothane concentrations and ventilatory rate were also recorded. 2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1. Maximum mean end-tidal carbon dioxide concentration and minimum mean ventilatory rate occurred 8 min after administration of oxycodone but the minimum mean peripheral arteriolar oxygen saturation occurred at 4 min. 3. Oxycodone (0.1 mg kg-1) appears to cause greater ventilatory depression than comparable analgesic doses of other opioids.
DOI:10.1111/j.1365-2125.1994.tb04324.x      PMID:7742170      URL    
[本文引用:1]
[11] GAJRAJ R J,DOI M,MANTZARIDIS H,et al.Analysis of the EEG bispectrum,auditory evoked potentials and th eEEG powers pectrum during repeated transitions from consciousness to unconsdousness[J].Br J Anaesth,1998,80:46-52.
We have compared the auditory evoked potential (AEP) index (a numerical index derived from the AEP), 95% spectral edge frequency (SEF), median frequency (MF) and the bispectral index (BIS) during alternating periods of consciousness and unconsciousness produced by target-controlled infusions of propofol. We studied 12 patients undergoing hip or knee replacement under spinal anaesthesia. During periods of consciousness and unconsciousness, respective mean values for the four measurements were: AEP index, 60.8 (SD 13.7) and 37.6 (6.5); BIS, 85.1 (8.2) and 66.8 (10.5); SEF, 24.2 (2.2) and 18.7 (2.1); and MF, 10.9 (3.3) and 8.8 (2.0). Threshold values with a specificity of 100% for a state of unconsciousness were: AEP index, 37 (sensitivity 52%); BIS, 55 (sensitivity 15%); and SEF, 16.0 (sensitivity 9%). There was no recorded value for MF that was 100% specific for unconsciousness. Of the four measurements, only AEP index demonstrated a significant difference (P < 0.05) between all mean values 1 min before recovery of consciousness and all mean values 1 min after recovery of consciousness. Our findings suggest that of the four electrophysiological variables, AEP index was best at distinguishing the transition from unconsciousness to consciousness.
DOI:10.1093/bja/80.1.46      PMID:9505777      URL    
[本文引用:1]
[12] HAO G T,ZHOU H Y,GAO H Z,et al.Pharmaco-kinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain[J].Pharm Rep,2014,66(1):153-158.
The aim of this study is to evaluate the pharmacokinetic profile of oxycodone and three of its metabolites, noroxycodone, oxymorphone and noroxymorphone after intravenous administration in Chinese patients with pain.Forty-two subjects were assigned to receive intravenous administration of oxycodone hydrochloride of 2.5, 5 or 10 mg. Plasma and urine samples were collected for up to 24 h after intravenous administration of oxycodone hydrochloride.Pharmacokinetic parameters showed that mean values of C(max), AUC(0-t) and AUC(0- ) of oxycodone were dose dependent, whereas Tmax and t(1/2) were not. The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively. Oxycodone and its three metabolites were excreted from urine. Approximately 10% of unchanged oxycodone was recovered in 24 h. Most adverse events (AEs) reported were mild to moderate. The frequently occurred AEs were dizziness, nausea, vomiting, drowsiness and fatigue. No dose-related AEs were found.Our pharmacokinetics of oxycodone injection in Chinese patients with pain strongly support continued development of oxycodone as an effective analgesic drug in China.
DOI:10.1016/j.pharep.2013.08.012      PMID:24905321      URL    
[本文引用:1]
资源
PDF下载数    
RichHTML 浏览数    
摘要点击数    

分享
导出

相关文章:
关键词(key words)
羟考酮
盐酸
呼吸抑制
镇静

Oxycodone hydrochloride
Respiration inhibition
Sedation

作者
于翠萍
范婷
王培

YU Cuiping
FAN Ting
WANG Pei